Literature DB >> 16455883

Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Thomas Akerlund1, Bo Svenungsson, Asa Lagergren, Lars G Burman.   

Abstract

We investigated in vivo and in vitro yields of toxins A and B from and PCR ribotypes of Clostridium difficile isolates from 164 patients with differing severities of C. difficile-associated diarrhea (CDAD) (patients were grouped as follows: <3 loose stools per day, n = 45; 3 to 10 per day, n = 97; >10 per day, n = 22). The median fecal toxin levels in each group were 0.5, 6.8, and 149 U/g feces (P < 0.001), respectively. Patients with severe diarrhea also had more-frequent occurrence of blood in stool and vomiting, but there was no association with fecal toxin levels per se. There was no correlation between fecal toxin level and toxin yield in vitro for the corresponding C. difficile isolate or between its PCR ribotype and disease severity. A broad range of toxin yields among isolates belonging to major PCR ribotypes indicated a presence of many subtypes. We hypothesize that bacterial and host factors that affect C. difficile toxin levels in feces are important determinants of symptoms in CDAD patients. An inverse correlation between toxin yield and spore count (r = 0.66) in stationary-phase cultures supported the notion that toxin production and sporulation represent opposite alternative survival strategies for C. difficile cells facing nutrient shortage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455883      PMCID: PMC1392646          DOI: 10.1128/JCM.44.2.353-358.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.

Authors:  S Karlsson; A Lindberg; E Norin; L G Burman; T Akerlund
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Clostridium difficile--associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results.

Authors:  S H Cheng; J J Lu; T G Young; C L Perng; W M Chi
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

4.  Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile.

Authors:  P Bidet; V Lalande; B Salauze; B Burghoffer; V Avesani; M Delmée; A Rossier; F Barbut; J C Petit
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

5.  Dynamics of Clostridium difficile infection. Control using diet.

Authors:  P B Ward; G P Young
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

6.  Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1).

Authors:  Warren N Fawley; Peter Parnell; Paul Verity; Jane Freeman; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Subtyping of Clostridium difficile PCR ribotype 001 by REP-PCR and PFGE.

Authors:  Gemma Northey; Micaela Gal; Ahmed Rahmati; Jon S Brazier
Journal:  J Med Microbiol       Date:  2005-06       Impact factor: 2.472

8.  Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids.

Authors:  Sture Karlsson; Lars G Burman; Thomas Åkerlund
Journal:  Microbiology       Date:  1999-07       Impact factor: 2.777

9.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

10.  A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates.

Authors:  M Rupnik; V Avesani; M Janc; C von Eichel-Streiber; M Delmée
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more
  56 in total

1.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

2.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

Review 3.  Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection.

Authors:  Nira R Pollock
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

4.  Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Authors:  Michelle Merrigan; Anilrudh Venugopal; Michael Mallozzi; Bryan Roxas; V K Viswanathan; Stuart Johnson; Dale N Gerding; Gayatri Vedantam
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

5.  Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.

Authors:  Vladimir Beran; Dittmar Chmelar; Jana Vobejdova; Adela Konigova; Jakub Nemec; Josef Tvrdik
Journal:  Folia Microbiol (Praha)       Date:  2013-10-11       Impact factor: 2.099

6.  Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007.

Authors:  L Fenner; R Frei; M Gregory; M Dangel; A Stranden; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

7.  The A, B, BI, and Cs of Clostridium difficile.

Authors:  Erik R Dubberke
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.

Authors:  Sarah Underwood; Shuang Guan; Vinod Vijayasubhash; Simon D Baines; Luke Graham; Richard J Lewis; Mark H Wilcox; Keith Stephenson
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

9.  Analysis of ultra low genome conservation in Clostridium difficile.

Authors:  Joy Scaria; Lalit Ponnala; Tavan Janvilisri; Weiwei Yan; Lukas A Mueller; Yung-Fu Chang
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

10.  Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A.

Authors:  Ruth Murray; Dave Boyd; Paul N Levett; Michael R Mulvey; Michelle J Alfa
Journal:  BMC Infect Dis       Date:  2009-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.